Catalent, Inc. Announces Secondary Public Offering of Common Stock
06 September 2016 - 11:22PM
Business Wire
Catalent, Inc. (“Catalent”) (NYSE:CTLT), the leading global
provider of advanced delivery technologies and development
solutions for drugs, biologics and consumer health products, today
announced the launch of a secondary public offering of its common
stock. Certain stockholders of Catalent (the “Selling
Stockholders”) are offering for sale to the public all of the
approximately 19.0 million shares of Catalent’s common stock owned
by them. Catalent is not offering any stock in this transaction and
will not receive any proceeds from the sale of the shares by the
Selling Stockholders.
Goldman, Sachs & Co., Deutsche Bank Securities and Morgan
Stanley are acting as underwriters for the offering.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described above, nor
shall there be any sale of such shares of common stock in any state
or jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
The offering of the shares of common stock will be made pursuant
to an effective shelf registration statement. The offering will be
made only by means of a prospectus, copies of which may be obtained
from Goldman, Sachs & Co., Attn: Prospectus Department, 200
West Street, New York, NY 10282, telephone:1-866-471-2526,
facsimile: 212-902-9316, e-mail: prospectus-ny@ny.email.gs.com;
Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall
Street, New York, New York 10005, telephone: (800) 503-4611 or
email prospectus.cpdg@db.com; or Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, NY 10014. The registration statement is available on the
SEC’s website at www.sec.gov under the
registrant’s name.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. You can identify these forward-looking statements by the
use of words such as “outlook,” “believes,” “expects,” “potential,”
“continues,” “may,” “will,” “should,” “could,” “seeks,” “projects,”
“predicts,” “intends,” “plans,” “estimates,” “anticipates” or the
negative version of these words or other comparable words and
include all discussions of the contemplated secondary public
offering. Such forward-looking statements are subject to various
risks and uncertainties, including (a) any decision by the Selling
Stockholders or the underwriters not to proceed with the proposed
secondary offering, (b) market conditions making the secondary
offering unattractive to potential purchasers of the offered shares
of common stock, and (c) those risks and uncertainties described
under the section entitled “Part I —Item 1A. Risk Factors” of
Catalent’s Annual Report on Form 10-K for the fiscal year ended
June 30, 2016, filed with the SEC, as such factors may be updated
from time to time in Catalent’s periodic filings with the SEC,
which are accessible on the SEC’s website at www.sec.gov.
Accordingly, there are or will be important factors that could
cause actual outcomes or results to differ materially from those
indicated in these statements. These factors should not be
construed as exhaustive and should be read in conjunction with the
other cautionary statements that are included in Catalent’s filings
with the SEC. Catalent undertakes no obligation to publicly update
or review any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as required
by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160906006591/en/
Investors:Catalent, Inc.Thomas Castellano,
732-537-6325investors@catalent.com
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024